

ESM Table 2. Change in HbA_{1c} from baseline at week 52 (ITT population)

	Placebo <i>(n = 99)</i>	Albiglutide 30 mg weekly <i>(n = 100)</i>	Albiglutide 50 mg weekly <i>(n = 97)</i>
HbA_{1c} (%) [mmol/mol]			
Baseline, mean (SD)	8.02 (0.908) [64.15 (9.93)]	8.05 (0.867) [64.47 (9.48)]	8.21 (0.942) [66.22 (10.30)]
Week 52, mean (SD)	8.20 (1.458) [66.11 (15.94)]	7.35 (1.150) [56.82 (12.57)]	7.29 (1.104) [56.17 (12.07)]
Model-adjusted change from baseline^a			
% difference (SE)	0.15% (0.097)	-0.70% (0.096)	-0.89% (0.097)
Difference from placebo			
% difference of least-squares means		-0.84%	-1.04%
95% CI		(-1.11 to 0.58)	(-1.31 to -0.77)
Superiority <i>P</i> value		<0.0001	<0.0001
Sensitivity analysis^b			
Model-adjusted change from baseline^c			
% difference (SE)	-0.15% (0.091)	-0.85% (0.077)	-1.09% (0.081)
Difference from placebo			
% difference of least-squares means		-0.70%	-0.94%
95% CI		(-0.94 to -0.47)	(-1.18 to 0.70)

Superiority <i>P</i> value		<0.0001	<0.0001
----------------------------	--	---------	---------

HbA_{1c}, glycosylated hemoglobin; SD, standard deviation; SE, standard error. ^aAdjusted for treatment group, region, history of prior myocardial infarction, and age category as factors and baseline HbA_{1c}. ^bSensitivity analyses were performed post hoc at the primary endpoint. ^cBased on mixed-model repeated measured analysis.